Companies
Amyris
the Emeryville synthetic-biology firm built a Lab-to-Market platform turning plant sugars into molecules like squalane and ambroxide, amassing about 700 patents and 16 products before a 1.15-billion-dollar debt crisis drove a 2023 Chapter 11 reorganization and a pivot to B2B ingredient supply.
- Country
- United States
- Ticker
- AMRS
Post-Chapter 11 B2B
Coverage
| CN | EU | US | |
|---|---|---|---|
| platform-chemicals | ✓ | ✓ | ✓ |
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaefsareach
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic specialty & fine chemicals (precision fermentation, biocatalysis, biorefinery) | specialty-fine-chem | Medium | → |
| Terpenes & terpenoids as platform molecules | platform-chemicals | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.